SinoMab BioScience EBITDA margin
What is the EBITDA margin of SinoMab BioScience?
The EBITDA margin of SinoMab BioScience Limited is 13,925.90%
What is the definition of EBITDA margin?
EBITDA margin is a profitability ratio that measures how much EBITDA the company generates as a percentage of revenue.
ttm (trailing twelve months)
EBITDA margin measures how much of EBITDA is generated as a percentage of sales. It measures the company’s operating profit as a percentage of its revenue and is calculated as EBITDA (earnings before interest, taxes, depreciation, and amortization) divided by total revenue.
EBITDA margin also helps with judging the effectiveness of cost-cutting processes at the company. The higher the company’s EBITDA margin, the lower operating expenses are in respect to revenue. As a result, a higher EBITDA margin is considered more favorable. Smaller companies can have higher EBITDA margins since they are able to operate more efficiently and maximize their profitability.
EBITDA excludes interest on debt, taxes, and capital expenditures, the margin does not provide a perfectly clear estimate of the business’s cash flow generation. Furthermore, EBITDA margin is not recognized as a GAAP (generally accepted accounting principles) metric.
EBITDA margin of companies in the Health Care sector on HKSE compared to SinoMab BioScience
What does SinoMab BioScience do?
SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases, primarily monoclonal antibody (mAb)-based biologics. Its flagship product is SM03, a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA), as well as in various clinical stages for other immunological diseases, such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company also focuses on developing SN1011, a Bruton's tyrosine kinase inhibitor, which is Phase I clinical trial for the treatment of RA, SLE, pemphigus, multiple sclerosis, and other immunological diseases. Its products under preclinical stage comprise SM17 for the treatment of asthma and idiopathic pulmonary fibrosis; SM09 that is used for the treatment of NHL and RA; SM06 for use in treating RA, SLE, and SS; and TNF2 for the treatment of RA. The company operates in Mainland China, the Cayman Islands, and Hong Kong. SinoMab BioScience Limited was incorporated in 2001 and is headquartered in Pak Shek Kok, Hong Kong.
Companies with ebitda margin similar to SinoMab BioScience
- Horseshoe Metals has EBITDA margin of 8,935.63%
- Kaili Resources has EBITDA margin of 9,119.88%
- Red Sky has EBITDA margin of 9,289.83%
- Exore Resources has EBITDA margin of 10,362.46%
- Gold Reserve has EBITDA margin of 10,882.26%
- Volt Resources has EBITDA margin of 12,108.33%
- SinoMab BioScience has EBITDA margin of 13,925.90%
- Satellos Bioscience Inc has EBITDA margin of 13,993.40%
- Australian Vanadium has EBITDA margin of 14,193.04%
- Australian Vanadium has EBITDA margin of 14,193.04%
- Sprott Physical Gold Trust has EBITDA margin of 14,706.31%
- Red Hill Iron has EBITDA margin of 15,048.31%
- Transport of India has EBITDA margin of 16,294.76%